Lista de obras -

A case series of COVID-19 patients with chronic hepatitis B virus infection

scientific article published on 19 June 2020

A comprehensive, longitudinal analysis of humoral responses specific to four recombinant antigens of SARS-CoV-2 in severe and non-severe COVID-19 patients

scientific article published on 10 September 2020

A novel index using routinely clinical parameters for predicting significant liver inflammation in chronic hepatitis B.

artículo científico publicado en 2018

A novel non‐invasive model for the prediction of advanced liver fibrosis in chronic hepatitis B patients with NAFLD

scientific article published in 2023

A scoring model for predicting prognosis of patients with severe fever with thrombocytopenia syndrome.

artículo científico publicado en 2017

Clinical characteristics of a case series of children with coronavirus disease 2019

scientific article published on 08 April 2020

Clinical features of COVID-19 patients with non-alcoholic fatty liver disease

artículo científico publicado en 2020

Clinical findings of patients with coronavirus disease 2019 in Jiangsu province, China: A retrospective, multi-center study

scientific article published on 08 May 2020

Emodin Alleviates Liver Fibrosis of Mice by Reducing Infiltration of Gr1hi Monocytes.

artículo científico publicado en 2018

Epidemiological and clinical features of asymptomatic patients with SARS-CoV-2 infection

artículo científico publicado en 2020

Hepatitis B virus-induced hyperactivation of B cells in chronic hepatitis B patients via TLR4

artículo científico publicado en 2020

High hepatitis C virus cure rates with approved interferon-free direct-acting antivirals among diverse mainland Chinese patients including genotypes 3a and 3b

artículo científico publicado en 2020

Letter: clinical outcomes after long-term entecavir or tenofovir treatment in patients with hepatitis D and advanced fibrosis

artículo científico publicado en 2019

Letter: distinct hepatitis B virus relapse rates after discontinuing tenofovir and entecavir therapy in chronic hepatitis B patients

artículo científico publicado en 2019

Letter: hepatitis B virus reactivation in patients with chronic hepatitis C during direct-acting anti-viral therapy.

artículo científico publicado en 2017

Letter: lipid-lowering effect of tenofovir disoproxil fumarate in chronic hepatitis B-more evidence is needed

artículo científico publicado en 2017

Letter: more studies are needed to elucidate the impact of HBV/HCV coinfection on cirrhosis and its consequences.

artículo científico publicado en 2018

Letter: programmed death-1-a predictor for antiviral treatment in chronic hepatitis B. Authors' reply

artículo científico publicado en 2020

Letter: rates and determinants of significant liver inflammation in chronic hepatitis B virus-infected patients with low ALT levels in the absence of significant fibrosis

artículo científico publicado en 2021

Letter: risk of developing hepatocellular carcinoma in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation

scientific article published on 01 September 2019

Letter: the potential risk of HBV reactivation in patients with resolved HBV infection during direct-acting antiviral therapy

artículo científico publicado en 2017

Letter: use of collagen proportionate area to quantify liver fibrosis and predict clinical outcomes in non-alcoholic fatty liver disease

scientific article published on 01 August 2019

Non-invasive fibrosis markers for chronic hepatitis B in sub-Saharan Africa.

artículo científico publicado en 2017

Overweight and obesity are risks factors of severe illness in patients with COVID-19

scientific article published on 31 July 2020

Plateletcrit as a potential index for predicting liver fibrosis in chronic hepatitis B

scientific article published on 25 January 2020

Profiles of serum soluble programmed death-1 and programmed death-ligand 1 levels in chronic hepatitis B virus-infected patients with different disease phases and after anti-viral treatment

scientific article published on 03 May 2020

Reply to the letter by Beyan et al "Plateletcrit may not be an index for predicting of liver fibrosis in patients with chronic hepatitis B"

scientific article published on 20 March 2020

Risk factors of liver injury in patients with coronavirus disease 2019 in Jiangsu, China: a retrospective, multi-center study

artículo científico publicado en 2020

Surveillance of SARS-CoV-2 infection among frontline health care workers in Wuhan during COVID-19 outbreak

artículo científico publicado en 2020

Lista de obras de

A case series of COVID-19 patients with chronic hepatitis B virus infection

A comprehensive, longitudinal analysis of humoral responses specific to four recombinant antigens of SARS-CoV-2 in severe and non-severe COVID-19 patients

A novel index using routinely clinical parameters for predicting significant liver inflammation in chronic hepatitis B.

A novel non‐invasive model for the prediction of advanced liver fibrosis in chronic hepatitis B patients with NAFLD

A scoring model for predicting prognosis of patients with severe fever with thrombocytopenia syndrome.

Clinical characteristics of a case series of children with coronavirus disease 2019

Clinical features of COVID-19 patients with non-alcoholic fatty liver disease

Clinical findings of patients with coronavirus disease 2019 in Jiangsu province, China: A retrospective, multi-center study

Emodin Alleviates Liver Fibrosis of Mice by Reducing Infiltration of Gr1hi Monocytes.

Epidemiological and clinical features of asymptomatic patients with SARS-CoV-2 infection

Hepatitis B virus-induced hyperactivation of B cells in chronic hepatitis B patients via TLR4

High hepatitis C virus cure rates with approved interferon-free direct-acting antivirals among diverse mainland Chinese patients including genotypes 3a and 3b

Letter: clinical outcomes after long-term entecavir or tenofovir treatment in patients with hepatitis D and advanced fibrosis

Letter: distinct hepatitis B virus relapse rates after discontinuing tenofovir and entecavir therapy in chronic hepatitis B patients

Letter: hepatitis B virus reactivation in patients with chronic hepatitis C during direct-acting anti-viral therapy.

Letter: lipid-lowering effect of tenofovir disoproxil fumarate in chronic hepatitis B-more evidence is needed

Letter: more studies are needed to elucidate the impact of HBV/HCV coinfection on cirrhosis and its consequences.

Letter: programmed death-1-a predictor for antiviral treatment in chronic hepatitis B. Authors' reply

Letter: rates and determinants of significant liver inflammation in chronic hepatitis B virus-infected patients with low ALT levels in the absence of significant fibrosis

Letter: risk of developing hepatocellular carcinoma in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation

Letter: the potential risk of HBV reactivation in patients with resolved HBV infection during direct-acting antiviral therapy

Letter: use of collagen proportionate area to quantify liver fibrosis and predict clinical outcomes in non-alcoholic fatty liver disease

Non-invasive fibrosis markers for chronic hepatitis B in sub-Saharan Africa.

Overweight and obesity are risks factors of severe illness in patients with COVID-19

Plateletcrit as a potential index for predicting liver fibrosis in chronic hepatitis B

Profiles of serum soluble programmed death-1 and programmed death-ligand 1 levels in chronic hepatitis B virus-infected patients with different disease phases and after anti-viral treatment

Reply to the letter by Beyan et al "Plateletcrit may not be an index for predicting of liver fibrosis in patients with chronic hepatitis B"

Risk factors of liver injury in patients with coronavirus disease 2019 in Jiangsu, China: a retrospective, multi-center study

Surveillance of SARS-CoV-2 infection among frontline health care workers in Wuhan during COVID-19 outbreak